Related Experiment Videos
Cyclical pamidronate infusions in postmenopausal osteoporosis
A Peretz1, J J Body, J C Dumon
1Department of Internal Medicine, Brugmann University Hospital, Brussels, Belgium.
Maturitas
|August 1, 1996
Summary
Cyclic pamidronate treatment effectively reduced bone turnover in postmenopausal osteoporosis. This bisphosphonate therapy led to a significant increase in lumbar spine bone mineral density over one year.
Area of Science:
- Endocrinology
- Bone Metabolism
- Pharmacology
Background:
- Pamidronate (APD) is a bisphosphonate for osteoporosis, but its use in this condition was less studied than etidronate.
- Investigating cyclic intravenous APD treatment in postmenopausal osteoporosis is crucial for understanding its therapeutic potential.
Purpose of the Study:
- To evaluate the efficacy of cyclic intravenous pamidronate (APD) in treating postmenopausal osteoporosis.
- To assess the impact of APD on bone turnover markers and bone mineral density (BMD).
Main Methods:
- 36 postmenopausal women with osteoporosis received five courses of APD.
- Treatment intervals were determined by urinary calcium excretion (UCa/Cr) levels.
- Bone turnover markers (BGP, ALP, UOHPro/Cr) and lumbar spine BMD (BMDL) were monitored.
Main Results:
- Bone turnover markers, including bone-GLA protein (BGP), alkaline phosphatase (ALP), and urinary hydroxyproline (UOHPro/Cr), significantly decreased.
- Serum calcium levels remained unchanged.
- Lumbar spine bone mineral density (BMDL) showed a significant increase of +2.9% after one year of treatment.
Conclusions:
- Cyclic pamidronate treatment is effective in reducing bone turnover in postmenopausal osteoporosis.
- The reduction in bone turnover is associated with a subsequent increase in vertebral bone mineral density.